Market Intelligence, Clinical Progress, and High-Purity Reagents for Signal Transduction & Resistance Modulator Development.
TarMart Solution Ecosystem & Related Targets
| Component / Network | Product Description | Product Link |
|---|---|---|
| WT Antigen | PLCG1 Recombinant Protein (Full-Length). High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Theoretical MW confirmed. | View PLCG1 Products |
| Domain Antigen (SH2 & Catalytic Core) | PLCG1 SH2 Domains (nSH2/cSH2) & Catalytic Core for protein-protein interaction and enzymatic assays. Verified folding. | View PLCG1 Products |
| Mutant Panel | PLCG1 Mutant Recombinant Proteins (e.g., S345F, R707Q, L833F, D1160H). Clinically relevant variants for resistance and activation mechanism studies. Sequence Verified. | View PLCG1 Products |
| Gene Delivery | PLCG1 Promise-ORF / Lentivirus. Full-length ORF with selectable markers for stable cell line generation in calcium-flux and reporter assays. | View PLCG1 Products |
| Benchmark Ab | Anti-PLCG1 & Anti-pY783 PLCG1 (Recombinant Rabbit mAb). Total and phospho-specific controls for Western/SPR/Cellular assay standardization. | View PLCG1 Products |
| Validator (siRNA) | PLCG1 siRNA Set (3 unique sequences). For knockdown verification and specificity controls. Endotoxin controlled. | View PLCG1 Products |
| Isoform Counterscreen | PLCG2 Recombinant Protein (Full-Length & Domains). Essential for PLCG1 vs PLCG2 selectivity assays. | View PLCG2 Products |
| Upstream Pathway Partner | EGFR Recombinant Protein (WT & Mutant ECD). Upstream kinase driving PLCG1 phosphorylation and activation. | View EGFR Products |
| Related Kinase | FGFR1 Recombinant Protein. Crucial kinase partner often co-dysregulated in PLCG1-driven signaling pathways. | View FGFR1 Products |
| Parallel Pathway | SHP2 (PTPN11) Recombinant Protein. Regulatory phosphatase for interaction studies. | View SHP2 Products |
Critical Assay Challenges and TarMart Solutions
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (PLCG1 vs PLCG2) | Human PLCG1 & PLCG2 ortholog proteins available with >95% purity; domain-truncated variants verified by mass spec; distinct isoform tags for unambiguous detection. |
| SH2 Domain / Phospho-Peptide Binding (PPI) | N- & C-SH2 domain proteins with verified folding; suitable for SPR/BLI and AlphaScreen. |
| Resistance & Activating Mutations | Pre-made Mutant Panel (S345F, R707Q, L833F, D1160H, and dbSNP variants) with theoretical MW confirmed; sequence verified for mechanistic assays. |
| Lack of Phosphorylation-Specific Controls | Phospho-Specific (pY783/pY775) & Total PLCG1 Benchmark Antibodies included. |
| Cell-Based Functional Readout (Ca2+ Flux) | PLCG1 Lentivirus for stable cell line construction; preserves native conformation in mammalian expression. |
| False Positives / Off-Target Effects | Validated PLCG1 siRNA Set included for specificity checks. |
| Instability of Multi-Domain Intracellular Proteins | Optimized expression systems (HEK293/Baculovirus); native folding and >95% purity by SDS-PAGE; high-concentration (>1mg/mL) for robust enzymatic assays. |
Live PLCG1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PLCG1-targeted therapeutics is intensifying as the industry confronts acquired resistance to upstream receptor tyrosine kinase (RTK) inhibitors. As an obligate signaling node downstream of EGFR, FGFR, and MET, PLCG1 represents a critical bypass resistance mechanism. Direct targeting remains an emerging frontier, with the majority of programs in discovery and preclinical phases. The field is converging on allosteric and orthosteric small molecule inhibitors, SH2 domain-mediated protein-protein interaction (PPI) blockers, and targeted protein degradation (PROTAC) strategies. As first-generation pathway inhibitors reach the clinic, the next wave of R&D is targeting isoform-selective inhibition to exploit the biological separation between PLCG1-driven oncogenic signaling and PLCG2-mediated hematopoietic functions. Combination therapies (e.g., EGFR + PLCG1) are also being explored to overcome resistance in NSCLC and colorectal cancers.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Allosteric/Orthosteric) | Deciphera, Nuvectis, Discovery-Stage Biopharma | Solid Tumors, CTCL | Enzymatic activity & selectivity (Need high-purity WT and mutant proteins) |
| PROTAC / Degrader | Arvinas, C4 Therapeutics | Refractory Solid Tumors, RTK-Resistant Cancers | Ternary complex validation (Need full-length protein for target engagement) |
| Peptide / PPI Blocker | Preclinical Research Groups | Immuno-Oncology, Autoimmunity | SH2 phosphopeptide binding (Need pY-peptide + SH2 domains) |
| RNAi / Antisense | Oligonucleotide Therapeutics Cos. | Autoimmune Disorders | Cellular knockdown readout (Need sequence-verified siRNA and lentivirus) |
| Combination (EGFR + PLCG1) | AstraZeneca, Daiichi Sankyo | NSCLC, CRC | Pathway activation panel (Need EGFR & PLCG1 co-reagents) |
| Immuno-Oncology (TCR signaling) | Novartis, Bristol Myers Squibb | T-cell Dysfunction | Calcium flux readout (Need lentivirus for stable reporter lines) |
Key Protein Domains and Clinically Relevant Mutations
PLCG1 (Phospholipase C Gamma 1) is a multidomain intracellular enzyme containing a PH domain (PH1), an EF-hand domain, and a PI-PLC X-box catalytic domain, as annotated in UniProt (P19174). Clinically relevant mutations include dbSNP variants rs2229348, rs2228246, and rs34203315, which are associated with altered signaling in oncology and immunity. Oncogenic activating mutations (e.g., S345F, R707Q, L833F, D1160H) are recurrently observed in T-cell lymphomas, angiosarcomas, and therapy-resistant solid tumors, driving the need for mutant-specific assay tools.